Navigation Links
InterCure Announces 100,000th RESPeRATE Unit Sold
Date:1/24/2008

Awareness and Adoption of Safe, Non-Drug Option to Lower Blood Pressure

Accelerates

NEW YORK, Jan. 24 /PRNewswire/ -- InterCure, Ltd. (Tel Aviv Stock Exchange: INCR) manufacturer of the RESPeRATE(R) hypertension treatment device, clinically-proven to significantly lower blood pressure, today announced it sold its 100,000th RESPeRATE device during the 2007 holiday season. This milestone marks a period of widespread consumer adoption and physician support for the novel technology and provides strong momentum for the RESPeRATE launch into retail pharmacies planned for later this year.

It took approximately four years to generate the first 50,000 unit sales of RESPeRATE, as clinical evidence, physician advocacy and consumer awareness began to take hold following the OTC clearance of the device. The second 50,000 units were sold in just 15 months. Growth is being driven through increased traction in the U.S. direct-to-consumer and online retail channels.

RESPeRATE has driven record volume through the world's leading e-commerce provider, Amazon.com, providing insight into the brand's sales potential within the retail environment. "RESPeRATE was among the top 100 items in our health and personal care store this holiday season," said Brett Barrilleaux, senior buyer at Amazon.com. "The brand's growth this year underscores our shoppers' desire for non-drug solutions in hypertension management."

"InterCure is experiencing robust growth in our core direct-to-consumer and online retail businesses. This reflects the growing consumer adoption rate for the RESPeRATE device and will serve us well as we expand our distribution into chain drugstores," said Erez Gavish, president and CEO of InterCure, manufacturer of the RESPeRATE device. "This year, we have been able to lay a solid foundation for our next phase of growth. Our traditional DTC business is healthier than it has ever been, and we have now assembled a world class consumer healthcare team to successfully launch into the retail market. This combination of momentum and expertise gives us great confidence as we head into a time of rapid acceleration in 2008."

About RESPeRATE

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure, Ltd.

InterCure, a medical device company, publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 100,000 units sold. With multiple published clinical studies, regulatory clearance in most key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Lisa Mokaba Brian Packard

Schwartz Communications InterCure, Inc.

781-684-0770 646-652-5800 x.7134

intercure@schwartz-pr.com bpackard@intercure.com


'/>"/>
SOURCE InterCure, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
2. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
3. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
4. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
5. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
6. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
7. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
8. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
9. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
10. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
11. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):